We studied GVHD after donor lymphocyte infusion (DLI) in 328 patients with relapsed CML between 1991 and 2004 . A total of 122 patients (38%) developed some form of GVHD. We analyzed GVHD by clinical presentation (acute or chronic GVHD) and onset time after the first DLI (early (p45 days) or late (445 days)). There was a significant overlap between onset time and clinical presentation. Some form of GVHD occurred at a median of 104 days, acute GVHD at 45 days and chronic GVHD at 181 days after DLI. The clinical presentation was acute GVHD in 71 patients, of whom 31 subsequently developed chronic GVHD subsequently. De novo chronic GVHD was seen in 51 patients. OS for all patients was 69% (95% confidence interval (CI) 63-75) at 5 years, DLIrelated mortality was 11% (95% CI 8-15) and diseaserelated mortality was 20% (95% CI 16-25). Risk factors for developing GVHD after DLI were T-cell dose at first DLI, the time interval from transplant to DLI and donor type. In time-dependent multivariate analysis, GVHD after DLI was associated with a risk of death of 2.3-fold compared with patients without GVHD. Clinical presentation as acute GVHD and early onset GVHD were associated with increased mortality.
Introduction
The description of the GVL effect paved the way for the development of donor lymphocyte infusions (DLI) for the treatment of relapse in patients after allogeneic hematopoietic SCT (HSCT). [1] [2] [3] [4] [5] [6] DLI is most effective in CML. 4 DLI can restore remission in many patients with CML relapsing after HSCT. [1] [2] [3] As response is less for advanced disease at the time of relapse, molecular/cytogenetic monitoring after transplantation and prompt therapy with DLI before developing hematological relapse may represent the optimal management of patients after transplantation. 7 The applicability of DLI in CML has been limited by morbidity and mortality associated with GVHD. 6, [8] [9] [10] Over the years, the practice of DLI has changed as the early bulk doses have been replaced by incremental dose regimens with low starting doses followed by escalating doses until achievement of response or development of GVHD. This may reduce the incidence and, more importantly, the severity of GVHD, while possibly preserving GVL's effects. 11, 12 Response to DLI has been reported in previous analyses by the Chronic Leukemia Working Party of the European Group for Blood and Transplantation (EBMT). 4, 13 The goal of this study was to describe in detail GVHD occurring after DLI with a focus on clinical presentation, time of onset, organ involvement, severity, clinical course, treatment and long-term outcome. In this retrospective study, GVHD after DLI was defined as acute or chronic depending on the typical clinical manifestations or the date of onset after DLI.
Patients and methods
This study was conducted by the Chronic Leukemia Working Party of the EBMT. Centers report minimum essential data (MED-A) to a central database for all transplants performed. Many centers also report a more comprehensive dataset (MED-B). Informed consent was obtained locally according to the regulations applicable at the time of transplant. Since 1 January 2003, the EBMT has required centers to confirm that written informed consent has been obtained before data acceptance. To complete the data set, special DLI forms (MED-C) were sent to all EBMT centers reporting patients who had received DLI for CML relapse. Out of 138 EBMT centers with 1045 patients receiving DLIs to treat CML in relapse, 31 participated in this study (see appendix). A total of 344 DLI forms were received and 328 patients had complete data for analysis. Each participating center completed the questionnaire for all consecutive patients eligible for the study in their institution, whereas non-participating centers reported none. This was audited against the EBMT database.
Definitions DLI. Lymphocytes were collected from the donors by leukapheresis on one or more occasions. Infusions had to be given on multiple days at least 7 days apart to be counted as separate infusions. Thirty-four (10%) patients treated with DLI had active GVHD at the time of infusion and 27 patients (8%) were still receiving some form of immunosuppressive therapy. GVHD newly diagnosed after DLI or progressing to higher grades after DLI was counted as post-DLI GVHD. Thirty-one patients received concomitant imatinib therapy with DLI, of which 12 (39%) developed GVHD after DLI.
Relapse. Relapse was classified as molecular (that is, BCR-ABL transcripts detected by quantitative reverse transcriptase PCR in two consecutive tests performed over a minimum of 4 weeks), cytogenetic (that is, reappearance of one or more Ph chromosome-positive metaphases at BM cytogenetics) or hematologic (that is, presence of peripheral blood leukocytosis accompanied by a hypercellular BM with Ph chromosome on cytogenetic analysis) in accordance with previous reports. 10, 12, 13 The phase of CML was classified in accordance with criteria proposed by the Center for International Blood and Marrow Transplant Research (CIBMTR). 14 
Outcomes
Acute and chronic GVHD occurring after DLI was reported and graded according to the standard clinical criteria (modified Glucksberg criteria for acute GVHD and chronic GVHD as defined by Shulman et al.) . [15] [16] [17] Centers reported GVHD as being acute or chronic according to the initial clinical presentation. However, as clinically acute and chronic GVHD occurring after DLI had overlapping onset times, the impact of GVHD on outcome was also analyzed by onset date from the first DLI. We defined early onset GVHD as GVHD occurring within 45 days after DLI (median onset time for acute GVHD) and late-onset GVHD as GVHD occurring after 45 days from the first DLI. Early and late GVHD did not correlate well with clinical presentation of GVHD: 47% of clinically acute GVHD had late onset and 20% of chronic GVHD after DLI was reported to be of early onset.
Myelosuppression after DLI was defined as a cytopenia (neutrophils o0.5 Â 10 9 /l or plts o20 Â 10 9 /l) unrelated to disease or chemotherapy. Survival was calculated from the date of the first infusion of donor lymphocytes until death or last follow-up. (EFS was calculated from the date of the first infusion of donor cells until the event or last followup). An event was defined as relapse after response, or, in patients not responding, as progression to a more advanced disease (for example, from cytogenetic relapse to hematological relapse or from chronic phase to accelerated phase). The DLI-related mortality was calculated from the date of the first infusion of donor cells until non-relapse death or last follow-up evaluation. Patients were censored at the last follow-up.
Statistical analysis
Cox regression models of GVHD and survival were run entering covariates associated (P ¼ 0.1) with outcome in univariate analysis. The following covariates were evaluated for their association with GVHD and survival after DLI: donor type, sex of donor, sex mismatch with the donor, phase at SCT, GVHD prophylaxis with T-cell depletion for SCT, stem cell source, interval from SCT to DLI, occurrence of GVHD after SCT, date of DLI, stage of relapse at time of DLI, initial cell dose (ICD) and interval from DLI to GVHD. The impact of GVHD on mortality was assessed by a time-dependent Cox model 18 entering GVHD as a time-dependent covariate with all patients being in the group without GVHD and entering into the GVHD risk sets at the time of onset.
Survival was calculated using the Kaplan-Meier estimator. 19 Estimates of GVHD, DLI-related mortality and disease-related mortality were by cumulative incidence with death from other causes defined as competing events.
Results
This study included 328 patients transplanted between 1983 and 2003 in 31 EBMT centers. They received DLI between 1991 and 2004 to treat CML relapse. None of the patients had received imatinib before transplantation. Median follow-up at the time of analysis of surviving patients was 50 months (range 4-167). Patient characteristics, the type of transplant they had received, the type of relapse, acute and chronic GVHD after transplantation, details of DLI, timing of DLI with respect to the date of transplant, number of DLI, T-cell dose received and the calendar year the DLI was received are detailed in Table 1 . Median time from HSCT to first DLI was 578 days (range 67-4296).
A total of 122 patients (37%) developed GVHD at any time after DLI. Acute grades II-IV GVHD was reported in 71 patients, of which 31 subsequently developed chronic GVHD. De novo chronic GVHD of any severity (not preceded by acute GVHD after DLI) was seen in 82 patients. The details of GVHD reported are specified in Table 2 . Of the 34 patients who had GVHD at the time of DLI, 8 were still on immunosuppressive therapy and 16 developed progression of GVHD after DLI. Of the patients who had extensive chronic GVHD at any time before DLI Outcome of GVHD after DLI after allo-BMT for CML Y Chalandon et al (n ¼ 56), 37 developed GVHD after DLI, 29 of which were chronic GVHD. We cannot differentiate between de novo GVHD after DLI and reactivation of pre-existing GVHD. GVHD after DLI was reported to occur at a median of 104 days (range 7-2341) after DLI (in 40 patients before day 45 and in 82 patients after day 45 from DLI). Acute GVHD (aGVHD) was reported to occur at a median of 45 days (range 11-599) after DLI ( Table 2 ). In patients with aGVHD, the median ICD was 1 Â 10 7 CD3 þ cells/kg (range 0.01-32), and 48% had received only one DLI dose (median 2, range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Acute GVHD treatment is described in Table 2 ; aGVHD resolved in 53% of patients within a median of 63 days (range 7-546) after onset. Eighty-two patients (25%) were reported to have chronic GVHD (cGVHD) ( Table 2) , of which 31 (38%) followed an initial phase of aGVHD after DLI. The median time of onset was 207 days (range 15-2341). Similar to aGVHD, the median ICD for those with cGVHD was 1 Â 10 7 CD3 þ cells/kg (range 0.05-40), and 55% of patients received only one DLI dose. Sixty-one patients are alive with a median follow-up of 50 months. cGVHD resolved in 39% of patients within a median of 354 days (range 44-1588) from onset.
The cumulative incidence of GVHD of any type at 5 years after DLI was 38% (95% confidence interval (CI) 32-43) (Figure 1a) . In univariate analysis, GVHD was more frequent in patients with a higher ICD (47% (95% CI 38-58) for 410 7 CD3 þ cells/kg vs 34% (95% CI 28-41) for o10 7 CD3 cells/kg, Po0.0001) (Figure 1b) , if the donor was unrelated vs related (48% (95% CI 40-58) vs 31% (95% CI 25-38), P ¼ 0.009), if the interval between transplant and DLI was o2 years vs longer (44% (95% CI 38-52) vs 27% (95% CI 20-36), P ¼ 0.001) and if the DLI was given before vs after 1998 (43% (95% CI 34-53) vs 36% (95% CI 30-44), P ¼ 0.044). The number of DLIs given was not analyzed as this is difficult to interpret taking into account that GVHD occurring after the first or second dose prevented the administration of additional doses. We do not have information on the planned number of doses. Hence, patients receiving 1-2 doses had a cumulative incidence of GVHD of 42% (95% CI 36-49), whereas patients receiving X3 doses had a cumulative incidence of GVHD of 26% (95% CI 18-37). There was a significant correlation between ICD and the number of doses received as 11% of recipients of X3 doses but 38% of recipients of 1-2 doses had an ICD of 410 7 CD3 þ cells/kg (Po0.0001). The multivariate model of risk factors for GVHD after DLI is shown in Table 3 . The concomitant use of imatinib was not associated with a significantly different risk of GVHD after DLI. In the multivariate analysis of GVHD risks, the relative risk (RR) was 1.18 (P ¼ 0.64). The 34 patients with pre-existing GVHD at the time of DLI did not differ significantly from the patients without GVHD in post-DLI GVHD risks and mortality.
In a multivariate analysis of mortality analyzing the impact of GVHD onset in a time-dependent manner, there was an increased risk of mortality with both early onset (p45 days) GVHD (RR of death 2.78 (1.6-4.8)) and late onset of GVHD (RR: 1.85 (1.04-3.3)) ( Table 4) . We tested for differences between early and late GVHD by breaking at the median onset time of all types of GVHD (that is, 104 days) and at the median onset time of aGVHD (45 days). There was a small difference in outcome with a breakpoint at 45 days, but there was none with a cutoff at 104 days. When analyzing the impact of GVHD on survival by clinical presentation, the initial presentation as acute GVHD was associated with a higher mortality (RR: 2.25 (1.38-3.67)), but chronic GVHD without prior acute GVHD after DLI was not (RR: 1.1 (0.62-1.94)) ( Table 4) . Other covariates in the model were disease stage at the time of DLI, and time interval from transplantation to DLI (o vs 42 years after transplantation).
The 5-year OS after DLI was 69% (95% CI 63-75) for all patients (Figure 2 ). EFS after DLI for the entire group was 63% (95% CI 57-69). DLI-related mortality was 11% (95% CI 8-15) for all patients and disease-related mortality was 20% (95% CI [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
Discussion
This study describes the characteristics of GVHD occurring after DLI for CML relapse in patients from the EBMT registry. This study confirms previous analyses that showed Outcome of GVHD after DLI after allo-BMT for CML Y Chalandon et al that GVHD presenting as acute (grade II-IV) and/or chronic GVHD is seen in 38% of patients after DLI, that the incidence of GVHD has decreased since 1998, that there is more GVHD with unrelated donors and with higher initial T-cell doses and with DLI given within 2 years after transplantation. GVHD after DLI is associated with a 2.3-fold increased mortality and early onset GVHD is slightly worse than GVHD of later onset after first DLI. Mortality is mainly seen with presentation as acute GVHD but not with presentation as purely cGVHD without prior aGVHD.
It is noted that the correlation between the GVHD onset date and the clinical presentation as acute or chronic GVHD is not very high. A significant percentage of GVHD reported clinically as acute had a late onset date and, similarly, an important proportion of GVHD reported as chronic was of early onset. This reflects the confusion between the definitions based on onset date and definitions based on clinical presentation. GVHD after DLI may be somewhat different from GVHD arising de novo after SCT. For instance, the time of onset of GVHD may be later after DLI. The median time to onset of acute GVHD after DLI 
P<0.0001
Initial cell dose > 10 7 <= 10 7 Outcome of GVHD after DLI after allo-BMT for CML Y Chalandon et al in our study was 45 days compared with 16-20 days after myeloablative T-replete HSCT. 20, 21 It is possible that both the pace and severity of GVHD are influenced by the use of intensive conditioning, the tissue damage, and inflammatory cytokines present after conventional SCT but not after DLI. 22 The target organs of acute GVHD after DLI seem the same as those seen after HSCT, but the clinical manifestations may differ. In one study, for example, a hepatitic variant of liver GVHD characterized by marked elevations of serum aminotransferase levels more than 10 times the upper limit of normal was observed in 15% of the patients who received DLIs. 23 Signs of both acute and chronic GVHD may develop simultaneously after DLI. 24 The risk factors for GVHD found in this study are similar to studies reported earlier. 6, 8, 10, 25, 26 Unrelated donors and higher ICD were associated with a higher risk. Patients receiving X3 doses had less GVHD than patients receiving only 1-2 doses. This was also described in the study of Raiola et al. 26 in a patient population with CML and other hematological malignancies, but in that study the cutoff was 4 doses. This association is impossible to study in an observational study as patients developing GVHD after a first or second dose do not usually receive additional doses. In addition, patients who do not develop GVHD after 1-2 doses are probably less prone to develop GVHD even if they received further DLI. In this sense, escalating doses of DLI could select patients who are capable of receiving (or indeed require) higher doses of T cells. GVHD was less frequent in patients transplanted after 1998 because in more recent years the bulk dose regimens used in the early 1990s were abandoned for incremental dose regimens. 11, 12 DLIs given 42 years after transplantation were associated with less GVHD than DLIs given within 2 years of SCT. It has been shown in animal models 27, 28 and in several studies that the further away DLIs are given from the original transplant date, the lesser GVHD is developed, 3, 4, 29, 30 although this remains controversial. 13, 31 This may be due to some form of tolerance induced by the previous transplant, the mechanisms of which remain to be elucidated.
As post-DLI GVHD and mortality risks did not differ in our study in patients with and without GVHD at the time of DLI, we must assume that the GVHD present at the time Outcome of GVHD after DLI after allo-BMT for CML Y Chalandon et al of DLI was either very mild or possibly misdiagnosed (subsided or non-active) in those 34 patients. It is noted that only 10 of the 34 patients had been reported with extensive chronic GVHD before DLI. GVHD after DLI may be de novo, but in patients who had had prior GVHD after the transplant this may be considered as a reactivation of pre-existing GVHD. We do not know whether this distinction is of importance and suggest that this issue requires further study. The concomitant use of imatinib was not associated with an increased risk of GVHD after DLI. However, the number of patients receiving imatinib was low and the power to detect a difference was therefore very limited. This study has several limitations. It is retrospective, multicentric and spans the period from 1991-2004. The 328 patients studied are a sample of 1045 patients in the EBMT database treated by DLI for relapse. A comparison of baseline characteristics and outcome with patients not considered for this study does not show major differences. The median follow-up was 50 months, which is relatively short as late events in patients with cGVHD may develop after many years. Survival is not the only issue with GVHD as this disease greatly affects the quality of life. Unfortunately, we lack data on the quality of life in affected patients.
Given the above, we suggest reporting GVHD after DLI by clinical manifestation, for example, as acute or chronic according to clinical presentation but to factor in the onset time ( þ /À 45 days from the first DLI) as a separator between these two entities.
In conclusion, this study shows that GVHD is a frequent complication of DLI and is associated with adverse outcome after DLI. Risk factors for GVHD include donor-recipient relationship and initial DLI dose as already shown in previous studies.
11 -13 Strategies to avoid GVHD after DLI should be favored.
